TY - JOUR T1 - JAK2 Specificity and Thrombosis Risk: Potential Role of Antiphospholipid Antibodies JF - The Journal of Rheumatology JO - J Rheumatol SP - 217 LP - 218 DO - 10.3899/jrheum.180722 VL - 46 IS - 2 AU - BRUCE M. ROTHSCHILD Y1 - 2019/02/01 UR - http://www.jrheum.org/content/46/2/217.abstract N2 - Janus kinase (JAK) inhibitors are a relatively new addition to our tools for treatment of rheumatoid arthritis (RA)1. They are responsible for transduction of more than 38 cytokinases2, with diffuse metabolic/immunologic implications. It is those immunologic effects that have attracted evaluation for modulation as a therapeutic approach to rheumatologic disease1. Infection and gastrointestinal perforation, liver abnormalities and serum creatinine, lipid and creatine phosphokinase level elevations may complicate all JAK inhibitors, but thrombotic events appear more limited to baricitinib3. Baricitinib has shown efficacy and is approved primarily for the treatment of RA. Not all JAK inhibitors are equal. … Address correspondence to Dr. B.M. Rothschild, 789 Bethel Road, Morgantown, West Virginia 26501, USA. E-mail: spondylair{at}gmail.com ER -